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Three types of nanocarriers from our group for imaging probes are reviewed here. Novel 
nanocarrierirs of “peptosome” and “lactosome” were prepared from amphiphilic polymers uniquely 
having a helical segment as a hydrophobic block. Apoferritin was chemically modified on the 
surface, and used for nanocontainer of a novel Gd-chelator. Lactosome was intensively studied and 




I for tumor imaging by NIRF, PET, and SPECT, respectively. 
Those labeled lactosomes are shown to be effective for tumor imaging on the basis of the EPR 
effect and the stealth property in vivo. The superiority of lactosome over other commercially 
available imaging agents is experimentally confirmed, which is explained by the dense and thick 
hydrophilic polymer brush formed on the surface and the helix bundles at the hydrophobic core. 
Our final goal is to develop the next-generation lactosome, which is the nanocarrier which is usable 









Cancer is one of the most common causes of death and 7.9 million of people died of cancer 
(around 13% of all deaths) in 2007.
1
 In order to improve the likelihood of cure and survival rate 
from cancer, cancer diagnosis at an early stage is essential. Recently, “molecular imaging”, which is 
an in vivo non-invasive visualization technique, is focused on. This technique detects biological 
phenomena specific to cancers by monitoring the behavior of probes in the living organisms. The 
technique is therefore spreading widely not only in the fundamental research areas for the 
elucidations of living system mechanisms, but also in applicative areas such as medicine and 
pharmaceutics. Various kinds of imaging modalities including computed tomography (CT), 
magnetic resonance (MR), positron emission tomography (PET), single photon emission computed 
tomography (SPECT), near-infrared optical imaging (NIRF) and so on, have been developed and 
utilized on medical purposes. Developments both of new highly sensitive imaging machines and 
probes including effective contrast agents are necessary for the early detection of cancer by 
molecular imaging techniques.  
To improve the sensitivity for the tumor detection, several strategies have been examined for 
molecular probes to target actively to tumor regions by using antibody
2
 and receptor-oriented 
ligands.
3,4
 On the other hand, the enhanced permeability and retention (EPR) effect, which is one of 
the well-known techniques, is also widely used for tumor targeting, even though the EPR effect is 
based on the passive targetting.
5-7
 In tumor tissues, submicron-sized defects exist on the vascular 
wall because of the rapid angiogenesis, enabling permeation of macromolecules through the wall. 
Further, the lymph system cannot overtake the rapid growth of the tumor, resulted in an inadequate 
ability to exclude foreign compounds from the tumor region. Accordingly, macromolecules and 
leukocytes, whose sizes are in the range of ca. 10–100 nm, are considered to be passively 
accumulated in the tumor region. 
5-7
  
On the basis of the concept of the EPR effect, various nanocarriers including polymeric 
micelles and vesicles, protein capsules, carbon nanotubes, dendrimers, quntum dots, and inorganic 
3 
 
nanoparticles have been applied for development of efficient tumor imaging probes.
8-12
 We have 
also synthesized and prepared nano-ordered particles with using self-assembling systems of 
amphiphilic polypeptide, polydepsipeptide, and protein. Here, we overview our works on the 
molecular assembly systems as well as other nanocarriers, and their utilization as nano-ordered 
carriers for tumor imaging on the basis of the EPR effect.  
 
2. Liposome and its analogues 
Micellar and vesicular molecular assemblies have been prepared from various amphiphilic 
compounds. Liposome, which was discovered in 1964 by Bangham et al.,
13
 is one of the most 
famous and widely utilized nano-carriers, and is made of the same components as cell lipid bilayer 
membranes. Liposome has been utilized as a nano-ordered carrier for drug delivery, since 
hydrophilic compounds can be encapsulated into the hollow space of liposome. There are more than 
ten commercially supplied liposome drugs.
14
 However, there are two intrinsic problems for 
liposome to be used in vivo as a nanocarrier. One is the physical stability of liposome. Hydrophobic 
interactions between alkyl chains are not strong enough for a long circulation in blood stream. Some 
additives such as cholesterol are normally mixed to the phospholipid for the membrane stabilization. 
The other problem is related with bio-defense systems. In our living system, liposome is opsonized 
by plasma proteins, quickly recognized as a foreign particle, and likely to be captured by the cells at 
reticulo-endothelial system (RES) of liver and spleen. Liposome surface is therefore modified so as 
to obtain an escape ability, the stealth property in other words, from RES. Actually, chemical 
modification of liposome with hydrophilic macromolecules such as poly(ethylene glycol) (PEG) is 
frequently adopted to prolong in vivo blood clearance time. The hydrophilic surface coating 
prevents the surface from opsonin adsorption, resulted in reduction of liposome uptake by RES.
15
 
PEGylated liposomal doxorubicin, Doxil®, is a typical example of the approved medical usage of 
the stealth liposome. 
16-18
  
In order to prepare physically stable molecular assemblies, various approaches have been 
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examined. Connecting two or more phospholipids by covalent cross-linking bonds is one approach. 
For example, diacetylenes are known to be polymerized topochemically by UV irradiation at 254 
nm to form a conjugated en-yne structure. Vesicular assembly was prepared from 
diyne-phospholipids, and was treated by the UV irradiation. The polymerized liposome shows 
extremely high stability against osmotic shock due to the formation of the conjugated en-yne 
network in the alkyl chains.
19-22
 
Organic-inorganic hybrid type vesicular assembly named “cerasome” was prepared from an 
artificial lipid bearing a trialkoxysilylated head with a dialkyl tail. Vesicular surface of the cerasome 
is partially coated with silica that is derived from acid hydrolysis of the trialkoxysilylated head 
groups. Owing to the siloxane network on the liposomal membrane surface, cerasome is infusible. 
Cerasome shows high morphological stability in aqueous solution, and it can be stored at least for 
several months at room temperature without any change.
23,24
 
These intermolecularly cross-linked molecular assemblies show high resistivity against 
morphological change, however, with loosing membrane fluidity and fusion ability, which are 
important properties for lipid membranes.  
 
3. Peptosome 
Vesicular assemblies consisted of amphiphilic block polymers are referred as 
“polymersome”.25-29 Compared with liposome, polymersomes are physically stable due to the 
strong intermolecular hydrophobic interactions of the long hydrophobic block. Various synthetic 
amphiphilic block polymers, whose hydrophobic block was consisted of poly(styrene), 
poly(butadiene) and so on, have been used for polymersomes. PEG is frequently used as a 
hydrophilic block in the amphiphilic block polymers due to the observation that PEGylated 
molecular assemblies are hardly recognized by bio-defense system as discussed above.  
Polypeptides are one of three major biomacromolecules, where the others are 
polysaccharides and nucleic acids, and are expected to show high biocompatibility and 
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biodegradability. Kataoka’s group is a pioneer in the studies on peptide molecular assemblies and 
their application for drug delivery system (DDS). A cationic amphiphile and an anionic amphipile 
both in aqueous solutions are mixed under specified concentrations to generate vesicles with a 
narrow size distribution. The peptide-based polyion complex vesicle is named as PICsome, which 
has an advantage to avoid use of organic solvent at preparation.
30,31
 
Polypeptides can be designed to take a specific conformation such as α-helix and β-sheet, 
which makes molecular assemblies have a well-defined structure. We thus have explored various 
amphiphilic polymers having a helix segment as a hydrophobic block about their molecular 
assemblies. In naturally occurring proteins, several motifs composed of helices such as coiled coil 
and four-helix bundle are frequently found out, indicating a good packing ability of peptide helices. 
Further, the molecular assemblies composed of helix bundles at the hydrophobic core region will 
exhibit a moderate elasticity because the helix bundles may generate shear stress with 
accompanying morphological distortion, which is in contrast to the rigid property of polymersomes 
due to the chain entanglements at the hydrophobic core region. Even though some rigidity is 
prerequisite for nanocarriers to be delivered suitably,
32
 highly rigid nanocarriers may have a concern 
to be stuck in very narrow blood capillaries. Nanocarriers with moderate elasticity are suitable for 
passing through blood capillaries, which will make in vivo half-life time of nanocarriers long.  
 
3.1. Peptosome having a PEG chain as a hydrophilic block 
Gramicidin A (g. A), a 15 mer peptide antibiotic is known to form ion channels in lipid 
bilayer membranes with taking a helical structure. Gramicidin A-poly(ethylene glycol) (PEG) 
conjugate was found out to form vesicles with a diameter in the range of 80–90 nm by 
self-assembling, which was reported in 1999 and named “peptosome” (Figure 1).33 The gramicidin 
A-PEG vesicles kept the vesicular morphology even at high concentrations of Triton X-100, which 
destroyed dimyristoylphosphatidylcholine (DMPC) liposomes. The gramicidin A blocks took a 
double helical structure which are tightly packed in the membrane region as illustrated in Figure 2. 
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Since then, several groups have reported on “peptosome”, showing possibility of peptide-based 





Figure 1. (a) Chemical structure of gramicidin A-poly(ethylene glycol) conjugate (b) Cryogenic 
temperature transmission electron microscope (Cryo-TEM) image of the gramicidin A-PEG 
assembly in water prepared by brief sonication using a probe-type sonicator. Vesicles as well as 
stuffed particles were observed. The stuffed particles have a multilamellar structure as shown in the 
inset image at the left-bottom corner (at the same magnification), which was out of focus to 
improve the contrast. There are several sites which show formation of unilamellar vesicles by 
stripping off the outer skin of the multilamellar particles (indicated by arrows). “Reprinted with 






Figure 2. Illustration of the helix peptide membrane of the gramicidin A (g. A)-PEG vesicles. 
“Reprinted with permission from Reference citation 33. Copyright 1999 American Chemical 
Society.” 
 
3.2. Peptosome having a disaccharide block 
PEG is allowed for medical and pharmaceutical usages. Even though PEG are regarded as 
biologically inert and having an escape ability from RES as described before, there are some reports 
on several adverse effects of PEGylated liposome on the human body, including complement 
activation.
43,44 
PEG is an artificial synthetic macromolecule and cannot be metabolized in our living 
system. Therefore, an alternative choice of the hydrophilic block of PEG with a biodegradable 
resource is expected to be developed. 
Hydrophobic helical peptide having lactose (Lac) as a hydrophilic block was synthesized 
and its self-assembly in water was studied.
45
 Cryogenic temperature transmission electron 
microscope (Cryo-TEM) observation and dynamic light scattering (DLS) measurment revealed that 
helical 8-mer glycopeptide, Nap-(Ala-Aib)4-NHCH2CH2NH-Lac formed vesicle in a diameter of 70 
nm with a narrow distribution. On the other hand, the dodecaglycopeptide gave fibrous assembly, 
and the hexadecapeptide could not be dispersed in water due to the highly hydrophobic property.  
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Sarcosine (N-methyl glycine) is a naturally occurring amino acid, and the structure is a part 
of creatine which helps to supply energy to muscle cells. It is degraded endogeneously by sarcosine 
dehydrogenase, and no side effects are reported except the sarcosinaemia. Nonionic and hydrophilic 
poly(Sar) chain is considered to have an advantage against poly(ethylene glycol) (PEG) chain on 
biodegradability due to the equipped metabolic pathway for sarcosine.  
Amphiphilic block polypeptide, poly(L-Glu(OMe))-block-poly(Sar) was synthesized using 
N-carboxyanhydride (NCA) polymerization techniques (Figure 3a).
46
 According to the hydrophilic 
and hydrophobic balance of the block polypeptides, poly(L-Glu(OMe))-block-poly(Sar) gave 
micelle with diameter of 30–40 nm and vesicle with diameter of 100–400 nm. Circular dichroic 
(CD) analysis indicated that hydrophobic peptide took α-helical structure. From the transmission 
electron microscopy (TEM) observation of the vesicular molecular assembly, the membrane 
thickness was estimated about 11 nm, suggesting that the hydrophobic helices took interdigitated 




Figure 3. Chemical structures of (a) poly(Glu(OMe))-block-poly(Sar), and (b) 
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poly(Leu-Aib)-block-poly(Sar) amphiphilic polypeptide. 
 
Both blocks of poly(L-Glu(OMe))-block-poly(Sar) were synthesized by a NCA 
polymerization method, therefore, resulting in the occurrence of polydispersity, despite of relatively 
small values, on their both hydrophilic and hydrophobic blocks. To avoid the polydispersity of the 
hydrophobic helical block, dodecapeptide of repeating Leu-Aib as a helical hydrophobic block was 
conjugated with poly(Sar) (Figure 3b).
47
 The amphiphilic block polypeptides also gave various 
morphological molecular assemblies according to the hydrophilic and hydrophobic balance of the 
polymer. In a Tris buffered solution (10 mM, pH 7.4), (Leu-Aib)6-block-poly(Sar)27 formed 
sheet-shaped molecular assembly. The sheet was highly homogeneous in size, and the average 
shape was a square with a side of ca. 200 nm (Figure 4a). Upon heating the solution at 90 °C for 10 
min, the sheet-shaped molecular assembly was transferred into the tubular assembly, whose 
diameter and length was ca. 60 nm, and ca. 200 nm, respectively (Figure 4b). The polydispersity 
index of the molecular assembly was lower than 0.1, indicating the highly homogenous assemblies 
being produced. 
Heating may have induced reduction of the total area of the unstable hydrophobic edges in 
the sheet-shaped assembly by transformation into the tubular structure. At the open mouths of the 
nanotube, hydrophobic blocks of the amphiphilic peptides were exposed in the same way as the 
edges of the sheet-shaped structures. Therefore, the peptide nanotube is also metastable. When the 
peptide nanotube solution was heated at 90 °C for 24 h, the nanotubes were partly elongated to 
double, triple, and quadruple lengths by sticking the unstable open mouths with each other (Figure 
4c). Interestingly, by mixing two amphiphilic block polypeptides having different poly(Sar) chain 
lengths, (Leu-Aib)6-block-poly(Sar)10 and (Leu-Aib)6-block-poly(Sar)27 (3:7 (w/w)), three way 





Figure 4. Negatively stained TEM images of the molecular assembly from 
(Leu-Aib)6-block-poly(Sar)27 (a) before heating, (b) after heating at 90 °C for 1 h, and (c) for 24 h. 
(d) TEM image of molecular assembly obtained from 3:7 (w/w) mixture of 
(Leu-Aib)6-block-poly(Sar)10 and (Leu-Aib)6-block-poly(Sar)27 after heating at 90 °C for 1 h. Bar = 
200 nm. “Reprinted with permission from Reference citation 47. Copyright Wiley-VCH Verlag 
GmbH & Co. KGaA.” 
 
3.3. Application of Peptosome for Tumor Imaging 
Poly(L-Glu(OMe))-block-poly(Sar) was labeled with near-infrared fluorescent molecule of 
indocyanine green (ICG), and ICG labeled molecular assembly was prepared from the 97:3 (wt/wt) 
mixture of non- and ICG-labeled amphiphilic polypeptides.
46
 In vivo retention time of the 
ICG-labeled peptosome in rat was determined by fluorescence measurements of the residual 
amounts of ICG in blood plasma. The peptosome showed relatively long half-life time, which is 
comparable to that of PEGylated liposome under the same experimental conditions.  
The ICG labeled peptosome or peptide micelle was intravenously administrated to the 
tumor-bearing mice and their disposition was traced using a near-infrared optical imaging system, 
IVIS-200 (Xenogen). In both cases, ICG-labeled molecular assemblies were gradually accumulated 
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in the tumor region, and the imaging contrast of the tumor region against the other healthy region 
became the highest after 2 or 3 days from the administration via tail vein (Figure 5), suggesting the 
EPR effect for the accumulation. The imaging contrast with using peptosome was better than that 
with using peptide micelle, because the smaller nanocarrier is leakier from blood vessels to increase 
the background fluorescence intensity.  
Peptosome keeps vesicular morphology in blood stream, as it was shown that encapsulated 
water-soluble agent and the component of peptosome were delivered together to the tumor site.
46
 
The peptosome membrane is thus stable in blood stream, and the helix stacking makes the 
membrane strong enough for delivering probes and drugs to tumor sites.  
 
 
Figure 5. In vivo cancer imaging using (b) NIRF-labeled peptosome and (d) peptide micelle. 
ICG-labeled peptosome was prepared from a mixture of GA-poly(Sar)43-block-poly(Glu(OMe))18 
and GA-poly(Sar)65-block-poly(Glu(OMe))18 (1:1) labeled with 3 wt% 
ICG-poly(Sar)63-block-poly(Glu(OMe))20. ICG-labeled peptide micelle was prepared from 
GA-poly(Sar)93-block-poly(Glu(OMe))12 labeled with 3 wt% 
ICG-poly(Sar)63-block-poly(Glu(OMe))20. (a, c) Bioluminescence image of SUIT2/EF-luc 
xenografts on the tumor-bearing mouse after administration of D-luciferin. (b, d) Image of 
fluorescence from ICG, 1 day after the administration of ICG-labeled peptosome, and peptide 
micelle, respectively. “Reprinted with permission from Reference citation 46. Copyright 2008 
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American Chemical Society.” 
 
In the same way with ICG labeled peptide micelle composed of 
poly(Glu(OMe))-block-poly(Sar), poly(Sar)-(Leu-Aib)8 (the degree of polymerization of the 
poly(Sar) block 60) micelle with 32 nm diameter also accumulated at the transplanted tumor region 
(Figure 6b).
48
 Therefore, peptide assemblies are considered to be effective nanocarriers for tumor 
imaging on the basis of the EPR effect. 
 
4. Lactosome 
Poly(L-lactic acid) (PLLA), which is biodegradable and biocompatible, is also known to take 
310 helical conformation. Similarly to peptosome and peptide micelle described above, amphiphilic 
PLLA-block-poly(Sar) polydepsipeptide self-assembled in aqueous solution with taking various 
morphologies in a dependent manner on the hydrophobic-hydrophilic balance (Figure 6a). We 





Figure 6. (a) Chemical structure of PLLA-block-poly(Sar) (the degrees of polymerization are 30 for 
the PLLA block and 90 for the poly(Sar) block, respectively) amphiphilic block polydepsipeptide. 
(b) Time lapase in vivo cancer imaging using ICG-labeled lactosome and Dy-776 labeled 
peptosome composed of poly(Sar)60-(Leu-Aib)8. 9-week-old nude mice, grafting SUIT-2/EF-Luc 
cells at front legs were used for the imaging. “Reprinted with permission from Reference citation 47. 
Copyright 2009 Elsevier.” 
 
PLLA terminal end was chemically modified with ICG.
47
 By mixing 3 wt% of the ICG 
labeled PLLA to the non-ICG labeled PLLA-block-poly(Sar) (the degrees of polymerization are 30 
for the PLLA block and 90 for the poly(Sar) block, respectively), ICG labeled lactosome 
(polydepsipeptide micelle) with diameter of 37 nm was prepared. The ICG labeled lactosome was 
intravenously administrated from the tail vein to the tumor-bearing mouse, and biodistribution of 
the fluorescent agent was traced by using optical imaging system, Clairvivo OPT (Shimadzu Corp.) 
(Figure 6b). Lactosome was accumulated at the transplanted tumor region within 24 hours. 
Importantly, uptake by RES of liver and spleen was drastically suppressed compared with 
ICG-labeled peptide micelle having a similar diameter. The cross section area of peptide chain with 
α-helical structure is about 5-fold larger than that of PLLA. Further, poly(Sar) chain length of 
lactosome is about 50% longer than that of peptide micelle. The hydrophilic shell of lactosome 
should be therefore thicker and denser than that of peptide micelle, which may be the reason for the 
better escape ability from the RES.  
Liver tumor imaging using macromolecular nano-ordered micelle is generally considered to 
be difficult because the micelle is trapped at healthy liver region by RES. Liver tumor imaging with 
lactosome was then challenged by using the HepG2 (Human hepatocellular liver carcinoma cell 
line) transplanted mice. The optical images, which were taken after 48 h from the administration, 
showed that the ICG fluorescence site overlapped at the luciferin bioluminescence site, which was a 
marker of HepG2. Ex vivo NIRF liver image also showed that ICG fluorescence was clearly 
14 
 
observed at the same place with the luciferin bioluminescence (Figure 7). Despite the orthotopic 
transplantation, lactosome accumulated at the tumor region with high efficiency by the EPR effect. 
Therefore, Lactosome is considered to be a powerful candidate of nanocarriers not only for tumor 
imaging but also for drug delivery system.  




I for tumor imaging by PET and SPECT, 
respectively. Those labeled lactosomes are preliminarily shown to be effective for imaging of 
subcutaneously grafted tumors, liver tumor, pancreas tumor, colon tumor and cerebral tumor, which 
reports are under preparation. 
 
 
Figure 7. Bright field, luciferin bioluminescence, and ICG fluorescence images of HepG2 
15 
 
hepatocellular carcinoma cell bearing mouse at liver (a–e), and its isolated liver (f–h). Strong signal 
was observed from the NIRF image of tumor bearing mouse at liver (b, e, h), where is the same 
place with luciferin bioluminescence (a, d, g). 
 
5. Apoferritin (Protein Capsule) 
Protein capsules are constructed by self-assembling of protein subunits into nano-cages. 
Apoferritin,
50-54
 viral capsids, DNA binding protein (Dps), small heat shock protein (sHsp) are 
well-known examples of the protein cages. Their utilization as nano-carriers for DDS and cancer 
imaging probe has been examined by taking advantages of their native hollow structure. There are 
many reactive groups on inner and outer surfaces of the protein cages, therefore, they can be easily 
chemically modified for functionalization.  
Apoferritin is an apoprotein, which consists of 24 protein subunits of two types (heavy and 
light chains), and forms a hollow cage-like structure with diameter of ca. 13 nm. It can encapsulate 
up to 4500 iron atoms as ferric oxyhydroxide form, and works as an iron storage protein named 
ferritin in our living system. According to the pH conditions, the 24 protein subunits of apoferritin 
can associate and disassociate reversibly, and various drugs and imaging agents can be encapsulated 
into the cavity. Using encapsulation ability in the cavity, application of apoferritin for nanocarriers 
like DDS has been examined.
55,56
 
Apoferritin-based MRI contrast agent is also investigated. For example, Aime et al. 
encapsulated a commercially available nonionic Gd-chelate, Gd-HPDO3A, in apoferritin cavity 
with using pH adjustment, and evaluated its performance as an MRI contrast agent.
57
 They 
chemically modified the surface of the Gd-loaded apoferritin with biotin. Utilizing the 
biotin-streptavidin specific binding system, the biotinylated Gd-loaded apoferritin bound to a tumor 







 were also encapsulated into apoferritin 
cavity to be utilized as MRI contrast agents. 
16 
 
We also developed a Gd-chelate-condensed type MRI contrast agent in apoferritin cavity 
and to perform tumor specific imaging on the basis of the EPR effect. Aime’s group reported that 
encapsulation efficiency of Gd-chelates into apoferritin was relatively low, and the amount of 
Gd-chelates encapsulated into each apoferritin was ca. 10.
51
 We designed a new cationic Gd-chelate, 
Gd-Me2DO2A, to improve the low yield of encapsulation. The uptake of the cationic Gd-chelate by 
apoferritin should be accelerated by the negative charges on the inner surface of apoferritin due to 
the localization of carboxylic residues (Figure 8). 
 
 
Figure 8. (a) Chemical structure of the newly designed cationic Gd-chelate, Gd-Me2DO2A, (b) 
Gd-chelate condensed type MRI contrast agent in apoferritin cavity using the electrostatic 
interaction between cationic Gd-Me2DO2A and anionic apoferritin inner surface. 
 
Encapsulation efficiency of Gd-Me2DO2A was improved as the increase of the encapsulated 
Gd-chelates per apoferritin from 6 for Gd-DOTA to 36 for Gd-Me2DO2A under the same 
preparative conditions. The proton relaxivity of Gd-Me2DO2A encapsulated in apoferritin was 
raised up to 35.9, which is ca. ten times higher than that of commercially available Gd-DOTA of 3.9 
(Fgiure 9a). The high relaxivity may be explainable by two factors: 1) the increased water 
coordination number and 2) the reduction of the rotation correlation time, so called the 
macromolecular effect. The latter is consistent with our interpretation that the encapsulated cationic 
Gd-chelates are immobilized on the negative charges at the inner surface of apoferritin.  
Apoferritin has a strong tendency to accumulate in liver by itself,
61
 which is a problem for 
17 
 
selective delivery of the Gd-chelate-loaded apoferritin to tumor tissues by the EPR effect. To solve 
the problem, the apoferritin surface was modified by dextran to prolong in vivo blood clearance 
time. MR imaging using human carcinoma transplanted mice showed that dextran coated apoferritin 
MRI contrast agent was delivered to the tumor region by the EPR effect, and the tumor region was 
precisely imaged with lower dosing amount of gadolinium compared with that of commercially 
available Gd-chelates MRI contrast agent, Gd-DOTA. 
 
 




We demonstrate that amphiphilic polypeptide or polydepsipeptide having helical structures 
in their hydrophobic blocks form nanocarriers with high physical stability.  Hydrophobic helical 
chains are regularly packed without chain entanglement in these molecular assemblies, resulting in 
showing moderate elasticity to circulate with long half time in blood stream. With controlling the 
hydrophilic-hydrophobic balance of the amphiphilic block polymers having a hydrophobic helical 
block, molecular assemblies of various morphologies, micelle, vesicle, nanotube, and three-way 
nanotube, are prepared.  
We have applied these nanocarriers for tumor imaging. These nanocarriers show good 
escape ability from bio-defense systems of living organisms and circulate stably in blood stream. At 
tumor regions, micelles with diameter of ca. 30 nm are leaked out from the blood vessels to be 
remained there by the EPR effect.  
18 
 
Cytotoxicity of the nanocarriers and/or their degradated products is one of the most 
important problems to overcome for the usage of nanocarriers on drug delivery system (DDS). Our 
nanocarriers are prepared from biocompatible and biodegradable materials such as polypeptide and 
proteins, and of great advantages on medical applications.  
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